Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas by Taron Miguel, Ichinose Yukito, Rosell Rafael, Mok Tony, Massuti Bartomeu, Zamora Lurdes, Mate Jose Luis, Manegold Christian, Ono Mayumi, Queralt Cristina, Jahan Thierry, Sanchez Jose Javier, Sanchez-Ronco Maria, Hsue Victor, Jablons David, Sanchez Jose Miguel, Moran Teresa in Clinical cancer research : an official journal of the American Association for Cancer Research (2005). PubMed

Abstract

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) confer a strong sensitivity to gefitinib, a selective tyrosine kinase inhibitor of EGFR.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.